Skip to main content

CASE REPORT article

Front. Oncol., 02 May 2024
Sec. Surgical Oncology

Spontaneous splenic rupture as the initial symptom of splenic angiosarcoma: case report and literature review

Peiwu JiangPeiwu Jiang1Xiaowen LiXiaowen Li2Jie ChenJie Chen2Du LiDu Li3Yehong Han*Yehong Han2*
  • 1Department of Vascular Surgery, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China
  • 2Department of General Surgery, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China
  • 3Department of Pathology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China

Spontaneous splenic rupture is an extremely rare occurrence, often attributed to tumorous pathologies. Among these, primary splenic angiosarcoma stands as a malignancy arising from the endothelial cells within the spleen. While sporadic cases have been reported globally, there remains a lack of comprehensive consensus on standardized approaches for diagnosis and treatment. We report a case of an 83-year-old male who underwent emergency enhanced CT due to sudden shock, revealing significant intra-abdominal fluid accumulation. Emergency surgery revealed splenic rupture necessitating splenectomy. Histopathological examination confirmed the diagnosis of splenic angiosarcoma. Despite successful surgery, the patient succumbed to severe complications two weeks postoperatively.

Introduction

The spleen, a crucial immune organ, rarely presents with tumors, whether they’re primary or secondary malignancies. Primary angiosarcoma of the spleen, also known as hemangiosarcoma, was initially documented by Langhans in 1879 (1). Reported cases of primary splenic angiosarcoma in English literature are fewer than 300. Despite its high malignancy, there’s a scarcity of comprehensive guidance in diagnosis and treatment, with only isolated experiences shared. In this context, we detail a case where the diagnosis was confirmed through splenectomy following spontaneous splenic rupture and subsequent hemorrhage. This case report aims to contribute insights into the diagnostic and therapeutic trajectory of this condition. It is noteworthy that the bleeding event occurred three days after initiating anticoagulant therapy.

Case description

An 83-year-old elderly male presented with abdominal discomfort. He has a history of hypertension and atrial fibrillation, managed with long-term oral amlodipine, maintaining good blood pressure control. However, he was not receiving anticoagulant therapy. He has no other chronic underlying diseases or family history of genetic disorders. Physical examination revealed no significant abnormalities. Investigations showed a significant elevation in D-dimer levels (16.85 mg/L) and a decrease in platelet count (37 * 10^9/L). Ultrasonography revealed splenomegaly with diffuse changes of undetermined etiology. CTPA suggested suspicious embolism in the pulmonary artery branches. Despite the bleeding risk, a cautious decision was made to initiate low-dose low molecular weight heparin anticoagulant therapy after weighing the risks and benefits. Due to concerns regarding excessive contrast agent use, an immediate enhanced CT scan of the spleen was not performed.

Three days later, the patient suddenly experienced severe left-sided abdominal pain accompanied by hypotension and tachycardia. Despite receiving large volumes of fluid resuscitation over several hours, there was no improvement. Emergency enhanced CT scan revealed a significant intra-abdominal hemorrhage with splenomegaly and multiple low-density lesions within the splenic parenchyma, showing mild enhancement on contrast administration. Initial consideration was given to intra-abdominal visceral bleeding (Figure 1). Emergency exploratory laparotomy unveiled around 4000ml of intraperitoneal hemorrhage and an actively bleeding splenic rupture (Figure 2), necessitating splenectomy. The patient received significant transfusions of packed red blood cells and plasma during the surgery. The surgery was timely and successful, rescuing the patient from hemorrhagic shock.

Figure 1
www.frontiersin.org

Figure 1 Enhanced CT scan reveals a large amount of fluid accumulation in the abdominal cavity. Multiple low-density nodules are visible within the spleen, accompanied by uneven density below the spleen. (A, B) Multiple low-density nodules are visible within the spleen. (C, D) Uneven density changes are observed on the inner side of the spleen.

Figure 2
www.frontiersin.org

Figure 2 The surgically removed spleen shows an approximately 0.5cm rupture with uneven surface coloration.

Following postoperative care, the patient was admitted to the intensive care unit (ICU) for hemodynamic stabilization, antimicrobial therapy, and adjunctive interventions. Subsequently, the patient underwent implantation of an inferior vena cava (IVC) filter for lower extremity deep vein thrombosis and underwent gastric repair surgery for stress ulcer perforation. Despite these measures, the patient remained hemodynamically unstable with persistent lactate accumulation. Regrettably, further therapeutic interventions were declined by the patient’s family, and the patient succumbed to his condition two weeks postoperatively.

The tumor cells in the spleen display significant heterogeneity and visible mitotic figures. Considering the Hematoxylin and Eosin (HE) staining (Figure 3) and immunohistochemical markers, the primary consideration is a vascular sarcoma. Immunohistochemical staining revealed partial positivity for CD31, CD8, ERG, FLI-1, Vimentin, with a Ki-67 index of 10-15% (Figure 4). Conversely, the tumor tested negative for CD68, D2-40, CD123, CD138, CD56, CD4, CD8, CD20, CD21, CD3, CD30, CD5, and BCL-6.

Figure 3
www.frontiersin.org

Figure 3 Pathological images and immunohistochemistry staining were performed, indicating significant tumor cell heterogeneity with visible nuclear division. [(A), HE×100]; [(B), HE×200]; [(C), HE×400].

Figure 4
www.frontiersin.org

Figure 4 The Ki-67 positive index is approximately 10-15%. [(A), ×A00]; [(B), HE×400].

Discussion

Splenic angiosarcoma originates from endothelial cells within blood vessels and exhibits significant invasiveness (2). Consequently, it is associated with high rates of local recurrence, systemic metastasis, and a short overall survival duration. Common sites of metastasis include intrasplenic spread and dissemination to the liver, lungs, and lymph nodes. There have also been reports of metastasis to the bone marrow, causing symptoms resembling hematological disorders. In certain cases, leukocytosis and thrombocytosis may occur (3).

According to statistical data, 80% of patients survive only six months following spontaneous splenic rupture, indicating a poor treatment outcome (4). Patients who undergo splenectomy before rupture have a slightly better prognosis, with survival extending up to 11 months (5). The increased risk of immediate mortality might be due to hypovolemic shock and disseminated intravascular coagulation caused by the rupture (6). It also heightens the risks of peritoneal and hematogenous dissemination. Montemayor et al. found that patients with splenic angiosarcoma who underwent splenectomy before rupture, rather than after rupture, had longer survival times (14.4 months vs. 4.4 months) (7).

The accurate preoperative diagnosis of this condition presents considerable challenges. Employing biopsy carries inherent risks, including the potential for bleeding and malignant dissemination (6). Consequently, histological confirmation typically occurs post-splenectomy, a procedure serving both diagnostic and therapeutic purposes.

Clinically, primary splenic angiosarcoma lacks distinctive symptoms, often presenting as anemia, splenomegaly accompanied by abdominal discomfort (75%), fatigue, weight loss, fever, hepatomegaly, splenomegaly, anemia, and thrombocytopenia. Approximately 30% of cases manifest with spontaneous splenic rupture as the initial symptom (8). There is an emerging perspective indicating that thrombocytopenia might serve as the primary symptom, even in the absence of anomalies in other laboratory tests.

While a conclusive diagnosis might not be achievable, the majority of angiosarcoma patients exhibit indications on imaging studies. The prevalent findings on ultrasound or CT scans encompass splenomegaly and inconclusive solid alterations within the spleen (9). Computed tomography illustrates splenomegaly accompanied by single or multiple nodular masses, displaying heterogeneous low attenuation. Lesion margins might manifest irregular or indistinct features, with contrast-enhanced scans revealing heterogeneous enhancement within the tumor.

Laboratory investigations linked to this condition commonly include anemia, thrombocytopenia, leukocytosis, and elevated erythrocyte sedimentation rate (1, 10). Apart from anemia, our patients do not present with these anomalies. Tumor markers (AFP, CEA, CA-125, and CA19-9) consistently remain within normal ranges or exhibit only slight elevations.

While challenging and without the potential for complete cure, surgical intervention remains the foremost therapeutic approach for splenic angiosarcoma. Determining the appropriate indications for surgically managing primary splenic tumors and splenic metastases presents inherent difficulties. Primary angiosarcoma or undifferentiated pleomorphic sarcoma, given their highly malignant nature, necessitate urgent surgical intervention. In cases where spleen involvement is limited in metastatic disease, splenectomy is considered a component of palliative measures when symptoms are prominent or as part of cytoreductive surgery (11).

Chemotherapy (such as taxanes, doxorubicin, liposomal doxorubicin, and ifosfamide) has been the primary treatment modality for advanced stage angiosarcoma. Anthracyclines like doxorubicin, doxorubicin analogs, and paclitaxel serve as active monotherapy options (12, 13). Reports on radiotherapy are scarce; however, based on observations from treating angiosarcomas in other locations, radiotherapy’s efficacy tends to be inferior compared to other types of sarcomas.

In our scenario, the patient initially reported discomfort in the upper abdomen. Despite multiple examinations showing nodular changes in the spleen, their exact nature remained uncertain. Given the concurrent diagnosis of pulmonary embolism, an immediate splenectomy wasn’t possible. Emergency surgery was eventually conducted after severe hemorrhagic shock, significantly impacting the patient’s overall survival. Hence, caution is necessary when encountering an enlarged spleen alongside low platelet count. When circumstances permit, opting for a preventive splenectomy appears to be a more cautious approach.

Conclusion

In our case, the presenting symptomatology comprised epigastric discomfort. Despite undergoing several examinations revealing nodular alterations within the spleen, conclusive determination of their etiology remained elusive. Given the concurrent diagnosis of pulmonary embolism, prompt planning for splenectomy was impeded.

Despite the emergent surgery performed for massive hemorrhagic shock, it undoubtedly precipitated a severe deterioration in survival time. Given the markedly elevated D-dimer levels and the diagnosis of pulmonary embolism, anticoagulant therapy was instituted. Subsequent to this intervention, there was an amelioration in D-dimer levels compared to baseline, albeit this may have precipitated the onset of the major bleeding event. Therefore, splenomegaly coupled with thrombocytopenia should raise suspicion, and radiographic abnormalities of the spleen should alert to the possibility of splenic neoplasms. Even in the presence of indications for anticoagulation, the use of anticoagulants should be approached cautiously.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by Ethics Committee of Hangzhou Hospital of Traditional Chinese Medicine. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article. Written informed consent was obtained from the participant/patient(s) for the publication of this case report.

Author contributions

PJ: Formal analysis, Writing – original draft, Writing – review & editing, Data curation, Investigation. XL: Writing – review & editing, Funding acquisition. JC: Writing – original draft. DL: Visualization, Writing – original draft. YH: Conceptualization, Supervision, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Zhejiang Traditional Medicine and Technology Program, China(Grant No.2024ZL625).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Falk S, Krishnan J, Meis JM. Primary angiosarcoma of the spleen. A clinicopathologic study of 40 cases. Am J Surg Pathol. (1993) 17:959–70. doi: 10.1097/00000478-199310000-00001

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Yang KF, Li Y, Wang DL, Yang JW, Wu SY, Xiao WD. Primary splenic angiosarcoma with liver metastasis: A case report and literature review. World J Gastroenterol. (2016) 22:3506–10. doi: 10.3748/wjg.v22.i12.3506

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Teco-Cortes JA, Navarrete-Pérez JJ, Sánchez-Castro ÓChecktae. Primary splenic angiosarcoma with capsular rupture and disseminated: a case report. Cir Cir. (2021) 89:59–63. doi: 10.24875/CIRU.21000118

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Hu S, Bueso-Ramos CE, Verstovsek S, Miranda RN, Yin CC, McDonnell T, et al. Metastatic splenic angiosarcoma presenting with thrombocytopenia and bone marrow fibrosis mimicking idiopathic thrombocytopenic purpura and primary myelofibrosis: a diagnostic challenge. Clin Lymphoma Myeloma Leuk. (2013) 13:629–33. doi: 10.1016/j.clml.2012.12.013

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Hsu JT, Chen HM, Lin CY, Yeh CN, Hwang TL, Jan YY, et al. Primary angiosarcoma of the spleen. J Surg Oncol. (2005) 92:312–6. doi: 10.1002/(ISSN)1096-9098

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Badiani R, Schaller G, Jain K, Swamy R, Gupta S. Angiosarcoma of the spleen presenting as spontaneous splenic rupture: A rare case report and review of the literature. Int J Surg Case Rep. (2013) 4:765–7. doi: 10.1016/j.ijscr.2013.06.007

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Montemayor P, Caggiano V. Primary hemangiosarcoma of the spleen associated with leukocytosis and abnormal spleen scan. Int Surg. (1980) 65:369–73.

PubMed Abstract | Google Scholar

8. Belli A, De Luca G, Bianco F, De Franciscis S, Tatangelo F, Romano GM, et al. An unusual metastatic site for primary lung cancer: the spleen. J Thorac Oncol. (2016) 11:128–9. doi: 10.1016/j.jtho.2015.08.005

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Vrachliotis TG, Bennett WF, Vaswani KK, Niemann TH, Bova JG. Primary angiosarcoma of the spleen–CT, MR, and sonographic characteristics: report of two cases. Abdom Imaging. (2000) 25:283–5. doi: 10.1007/s002610000034

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Neuhauser TS, Derringer GA, Thompson LD, Fanburg-Smith JC, Miettinen M, Saaristo A, et al. Splenic angiosarcoma: a clinicopathologic and immunophenotypic study of 28 cases. Mod Pathol. (2000) 13:978–87. doi: 10.1038/modpathol.3880178

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Huettl F, Lang H. [Surgery for primary splenic tumors and metastases of the spleen]. Chirurgie (Heidelb). (2023) 94:994–9. doi: 10.1007/s00104-023-01978-8

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Cao J, Wang J, He C, Fang M. Angiosarcoma: a review of diagnosis and current treatment. Am J Cancer Res. (2019) 9:2303–13.

PubMed Abstract | Google Scholar

13. Peng RQ, Xu BS, Liu YY, Yang QQ, Pan QZ, Zhang X. [Single-center study of different treatment for advanced or unresectable angiosarcoma patients]. Zhonghua Zhong Liu Za Zhi. (2023) 45:74–81. doi: 10.3760/cma.j.cn112152-20210507-00368

PubMed Abstract | CrossRef Full Text | Google Scholar

Keywords: angiosarcoma, immunohistochemistry, spleen, splenectomy, splenic rupture, case reprot

Citation: Jiang P, Li X, Chen J, Li D and Han Y (2024) Spontaneous splenic rupture as the initial symptom of splenic angiosarcoma: case report and literature review. Front. Oncol. 14:1366554. doi: 10.3389/fonc.2024.1366554

Received: 09 January 2024; Accepted: 03 April 2024;
Published: 02 May 2024.

Edited by:

Xiaofeng Yang, Temple University, United States

Reviewed by:

Arkady Bedzhanyan, Petrovsky National Research Center of Surgery, Russia
Edoardo Maria Muttillo, Sapienza University of Rome, Italy

Copyright © 2024 Jiang, Li, Chen, Li and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yehong Han, han.yehong@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.